Proteomic Identification of Dopamine-conjugated Proteins from Isolated Rat Brain Mitochondria and SH-SY5Y Cells

Overview

Journal Neurobiol Dis

Specialty Neurology

Date 2009 Apr 1

PMID 19332121

Citations 73

Authors

Victor S Van Laar

Amanda J Mishizen

Michael Cascio

Teresa G Hastings

Affiliations

Soon will be listed here.

Abstract

Dopamine oxidation has been previously demonstrated to cause dysfunction in mitochondrial respiration and membrane permeability, possibly related to covalent modification of critical proteins by the reactive dopamine quinone. However, specific mitochondrial protein targets have not been identified. In this study, we utilized proteomic techniques to identify proteins directly conjugated with (14)C-dopamine from isolated rat brain mitochondria exposed to radiolabeled dopamine quinone (150 microM) and differentiated SH-SY5Y cells treated with (14)C-dopamine (150 microM). We observed a subset of rat brain mitochondrial proteins that were covalently modified by (14)C-dopamine, including chaperonin, ubiquinol-cytochrome c reductase core protein 1, glucose regulated protein 75/mitochondrial HSP70/mortalin, mitofilin, and mitochondrial creatine kinase. We also found the Parkinson's disease associated proteins ubiquitin carboxy-terminal hydrolase L1 and DJ-1 to be covalently modified by dopamine in both brain mitochondrial preparations and SH-SY5Y cells. The susceptibility of the identified proteins to covalent modification by dopamine may carry implications for their role in the vulnerability of dopaminergic neurons in Parkinson's disease pathogenesis.

Citing Articles

Quantitative chemoproteomics reveals dopamine's protective modification of Tau.

Wang Q, Liu Z, Wang Y, Liu Y, Chen Y, Zhang S Nat Chem Biol. 2025; .

PMID: 39979588 DOI: 10.1038/s41589-025-01849-9.

Redox regulation, protein S-nitrosylation, and synapse loss in Alzheimer's and related dementias.

Oh C, Nakamura T, Zhang X, Lipton S Neuron. 2024; 112(23):3823-3850.

PMID: 39515322 PMC: 11624102. DOI: 10.1016/j.neuron.2024.10.013.

Ferroptosis-A Shared Mechanism for Parkinson's Disease and Type 2 Diabetes.

Duta C, Muscurel C, Dogaru C, Stoian I Int J Mol Sci. 2024; 25(16).

PMID: 39201524 PMC: 11354749. DOI: 10.3390/ijms25168838.

Cytosolic dopamine determines hypersensitivity to blunt force trauma.

Zuurbier K, Fonseca R, Arneaud S, Tatge L, Otuzoglu G, Wall J iScience. 2024; 27(6):110094.

PMID: 38883817 PMC: 11179581. DOI: 10.1016/j.isci.2024.110094.

Role of dopamine in the pathophysiology of Parkinson's disease.

Zhou Z, Yi L, Wang D, Lim T, Tan E Transl Neurodegener. 2023; 12(1):44.

PMID: 37718439 PMC: 10506345. DOI: 10.1186/s40035-023-00378-6.

References

Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S . The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci. 2003; 16(2):135-142. View

Xie J, Marusich M, Souda P, Whitelegge J, Capaldi R . The mitochondrial inner membrane protein mitofilin exists as a complex with SAM50, metaxins 1 and 2, coiled-coil-helix coiled-coil-helix domain-containing protein 3 and 6 and DnaJC11. FEBS Lett. 2007; 581(18):3545-9. DOI: 10.1016/j.febslet.2007.06.052. View

Okudo H, Urade R, Moriyama T, Kito M . Catalytic cysteine residues of ER-60 protease. FEBS Lett. 2000; 465(2-3):145-7. DOI: 10.1016/s0014-5793(99)01721-4. View

Sherer T, Betarbet R, Testa C, Seo B, Richardson J, Kim J . Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci. 2003; 23(34):10756-64. PMC: 6740985. View

Castegna A, Thongboonkerd V, Klein J, Lynn B, Markesbery W, Butterfield D . Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem. 2003; 85(6):1394-401. DOI: 10.1046/j.1471-4159.2003.01786.x. View

Cumming R, Andon N, Haynes P, Park M, Fischer W, Schubert D . Protein disulfide bond formation in the cytoplasm during oxidative stress. J Biol Chem. 2004; 279(21):21749-58. DOI: 10.1074/jbc.M312267200. View

Shi M, Caudle W, Zhang J . Biomarker discovery in neurodegenerative diseases: a proteomic approach. Neurobiol Dis. 2008; 35(2):157-64. PMC: 2939006. DOI: 10.1016/j.nbd.2008.09.004. View

Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E . The ubiquitin pathway in Parkinson's disease. Nature. 1998; 395(6701):451-2. DOI: 10.1038/26652. View

Halliwell B . Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 2001; 18(9):685-716. DOI: 10.2165/00002512-200118090-00004. View

10.

Gluck M, Ehrhart J, Jayatilleke E, Zeevalk G . Inhibition of brain mitochondrial respiration by dopamine: involvement of H(2)O(2) and hydroxyl radicals but not glutathione-protein-mixed disulfides. J Neurochem. 2002; 82(1):66-74. DOI: 10.1046/j.1471-4159.2002.00938.x. View

11.

Yaguchi T, Aida S, Kaul S, Wadhwa R . Involvement of mortalin in cellular senescence from the perspective of its mitochondrial import, chaperone, and oxidative stress management functions. Ann N Y Acad Sci. 2007; 1100:306-11. DOI: 10.1196/annals.1395.032. View

12.

Bonifati V, Rizzu P, van Baren M, Schaap O, Breedveld G, Krieger E . Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2002; 299(5604):256-9. DOI: 10.1126/science.1077209. View

13.

Aksenov M, Aksenova M, Butterfield D, Geddes J, Markesbery W . Protein oxidation in the brain in Alzheimer's disease. Neuroscience. 2001; 103(2):373-83. DOI: 10.1016/s0306-4522(00)00580-7. View

14.

Xu Y, Stokes A, Roskoski Jr R, Vrana K . Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res. 1998; 54(5):691-7. DOI: 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F. View

15.

Suh S, Hood B, Kim B, Conrads T, Veenstra T, Song B . Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics. 2004; 4(11):3401-12. DOI: 10.1002/pmic.200400971. View

16.

Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein J, Pierce W . Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002; 33(4):562-71. DOI: 10.1016/s0891-5849(02)00914-0. View

17.

Reed T, Perluigi M, Sultana R, Pierce W, Klein J, Turner D . Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis. 2008; 30(1):107-20. DOI: 10.1016/j.nbd.2007.12.007. View

18.

Berman S, Zigmond M, Hastings T . Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem. 1996; 67(2):593-600. DOI: 10.1046/j.1471-4159.1996.67020593.x. View

19.

Maker H, Weiss C, Brannan T . Amine-mediated toxicity. The effects of dopamine, norepinephrine, 5-hydroxytryptamine, 6-hydroxydopamine, ascorbate, glutathione and peroxide on the in vitro activities of creatine and adenylate kinases in the brain of the rat. Neuropharmacology. 1986; 25(1):25-32. DOI: 10.1016/0028-3908(86)90054-7. View

20.

Brenner-Lavie H, Klein E, Zuk R, Gazawi H, Ljubuncic P, Ben-Shachar D . Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia. Biochim Biophys Acta. 2007; 1777(2):173-85. DOI: 10.1016/j.bbabio.2007.10.006. View